STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 96 filers reported holding STOKE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,658 | +27.6% | 250,000 | 0.0% | 0.08% | -33.9% |
| Q1 2023 | $2,083 | -9.7% | 250,000 | 0.0% | 0.12% | -3.9% |
| Q4 2022 | $2,308 | -99.9% | 250,000 | 0.0% | 0.13% | -5.8% |
| Q3 2022 | $3,210,000 | -2.8% | 250,000 | 0.0% | 0.14% | -22.2% |
| Q2 2022 | $3,303,000 | -37.2% | 250,000 | 0.0% | 0.18% | -20.0% |
| Q1 2022 | $5,263,000 | -12.3% | 250,000 | 0.0% | 0.22% | +35.0% |
| Q4 2021 | $5,998,000 | -5.7% | 250,000 | 0.0% | 0.16% | +14.8% |
| Q3 2021 | $6,360,000 | -24.4% | 250,000 | 0.0% | 0.14% | -17.0% |
| Q2 2021 | $8,415,000 | -13.3% | 250,000 | 0.0% | 0.17% | -0.6% |
| Q1 2021 | $9,710,000 | -37.3% | 250,000 | 0.0% | 0.17% | -48.2% |
| Q4 2020 | $15,483,000 | +70.8% | 250,000 | -7.7% | 0.33% | +50.9% |
| Q3 2020 | $9,067,000 | +33.5% | 270,750 | -5.0% | 0.22% | +15.8% |
| Q2 2020 | $6,792,000 | +18.6% | 285,000 | +14.0% | 0.19% | -21.5% |
| Q1 2020 | $5,725,000 | – | 250,000 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |